<SEC-DOCUMENT>0001213900-25-084258.txt : 20250904
<SEC-HEADER>0001213900-25-084258.hdr.sgml : 20250904
<ACCEPTANCE-DATETIME>20250904063413
ACCESSION NUMBER:		0001213900-25-084258
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250904
DATE AS OF CHANGE:		20250904

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-79364
		FILM NUMBER:		251291850

	BUSINESS ADDRESS:	
		STREET 1:		501 E LAS OLAS BLVD
		STREET 2:		SUITE 300
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33301
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		501 E LAS OLAS BLVD
		STREET 2:		SUITE 300
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Strategic EP, LLC
		CENTRAL INDEX KEY:			0002081874
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		1050 CROWN POINTE PARKWAY
		STREET 2:		SUITE 500
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30338
		BUSINESS PHONE:		404-996-2817

	MAIL ADDRESS:	
		STREET 1:		1050 CROWN POINTE PARKWAY
		STREET 2:		SUITE 500
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30338
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Strategic EP, LLC -->
          <cik>0002081874</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>08/21/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001107421</issuerCik>
        <issuerName>Alaunos Therapeutics, Inc.</issuerName>
        <issuerCusip>98973P309</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>501 E. Las Olas Blvd.</com:street1>
          <com:street2>Suite 300</com:street2>
          <com:city>Fort Lauderdale</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>33301</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Strategic EP, LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>149827.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>149827.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>149827.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>6.8</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Does not include 62,299 shares of Common Stock issuable upon exercise of pre-funded warrants. These pre-funded warrants contain a provision, which precludes the exercise of the pre-funded warrants to the extent that, following exercise, the Reporting Person would own more than 4.99% (or, at the election of the holder, 9.99%) of the Common Stock outstanding. On August 26, 2025, the Reporting Person and the Issuer entered into a Standstill Agreement, pursuant to which the Issuer agreed to permit the Reporting Person to exceed the 4.99% ownership limitation, subject to an increase up to 9.99% as permitted under the terms of the pre-funded warrant agreement. In connection with the Standstill Agreement, the Reporting Person agreed to waive any rights to engage in takeover-related activities or otherwise seek to influence or control the Issuer.

The percentage is based on 2,205,716 shares of Common Stock outstanding as of August 20, 2025, as reported by the Issuer in its Form S-3 Registration Statement filed with the SEC on August 21, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Alaunos Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>501 E. Las Olas Blvd., Suite 300, Fort Lauderdale, FL 33301</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Strategic EP, LLC</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>1050 Crown Pointe Parkway, Suite 500, Atlanta, GA 30338</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Delaware</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>149,827 shares of Common Stock

Does not include 62,299 shares of Common Stock issuable upon exercise of pre-funded warrants. These pre-funded warrants contain a provision, which precludes the exercise of the pre-funded warrants to the extent that, following exercise, the Reporting Person would own more than 4.99% (or, at the election of the holder, 9.99%) of the Common Stock outstanding. On August 26, 2025, the Reporting Person and the Issuer entered into a Standstill Agreement, pursuant to which the Issuer agreed to permit the Reporting Person to exceed the 4.99% ownership limitation, subject to an increase up to 9.99% as permitted under the terms of the pre-funded warrant agreement. In connection with the Standstill Agreement, the Reporting Person agreed to waive any rights to engage in takeover-related activities or otherwise seek to influence or control the Issuer.</amountBeneficiallyOwned>
        <classPercent>6.8</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>149,827</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>149,827</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Strategic EP, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Alexander Chase Deitch</signature>
        <title>Alexander Chase Deitch/Manager</title>
        <date>09/04/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
